Navigation Links
Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
Date:11/8/2007

t of patient dosing.

Conference Call Details

Trubion will host a conference call and webcast to discuss the data presented at ACR. The call will be held today at 2 p.m. Pacific Time, 5 p.m. Eastern Time. The live event will be available from Trubion's Web site at http://investors.trubion.com/events.cfm, or by calling (888) 204-4368 or (913) 312-1303. A replay of the discussion will be available beginning later today from Trubion's Web site or by calling (888) 203-1112 or (719) 457-0820, and entering 4403352. The telephone replay will be available through Nov. 12, 2007.

About TRU-015 and SMIP(TM) Therapeutics

Trubion and Wyeth Pharmaceuticals are developing small modular immunopharmaceutical (SMIP) therapeutics directed to CD20, an antigen present on B cells. In addition to the ongoing development of TRU-015 for RA, investigational new drug applications have been filed for TRU-015 for systemic lupus erythematosus and non-Hodgkin's lymphoma. Trubion's SMIP drug candidates represent a novel class of immunotherapeutics that the company believes possess enhanced drug properties over monoclonal and recombinant antibodies. SMIP product candidates are novel single-chain polypeptide proteins designed using Trubion's custom drug assembly technology. Trubion's current product candidates bind to specific antigen targets on a cell's surface that have been clinically validated as important in disease management either by existing products or by potential products in clinical trials.

About Rheumatoid Arthritis

RA is a chronic disease, mainly characterized by inflammation of the lining, or synovium, of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. According to Datamonitor, RA is estimated to affect approximately 4.3 million people in the United States, Japan and Europe. In 2006, total reported worldwide sales of pro
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)...e/ -- The Michael J. Fox Foundation awarded a tota...teams for pre-clinical research on potential new t...ing was awarded under the Foundation,s Therapeuti...unched in 2006, supports and bolsters industry-foc...t of MJFF,s focus on ,de-risking, preclinical PD...
(Date:1/6/2009)...re/ -- Pacira Pharmaceuticals, Inc., an,acute car...y that enrollment,has been completed in two pivot... and efficacy of a single intraoperative administr...ged postoperative analgesia. , Results from...,arthroplasty (TKA) are expected to provide the p...
(Date:1/5/2009)...FirstCall/ -- Micromet, Inc.,(Nasdaq: MITI ), a...ietary,antibodies for the treatment of cancer, in...utlook on key events anticipated for the year 2009... on its research and development,programs at the ...: Update on several preclinical BiTE antibodies at...
(Date:12/30/2008)...wire/ -- The Coalition for 21st Century Medicine s...ntech, Inc. on December 5, 2008, seeking to restri... tests to physicians and patients. The request th... patient care and rests on flawed scientific and l...o encourage the research, development, and commerc...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference 30883 1Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference 30883 2EMS Magazine Announces Top Innovation Awards for 2008 30879 1EMS Magazine Announces Top Innovation Awards for 2008 30879 2Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 1Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 2Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 3Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 4Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 5Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 6Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 7IDO2 an active enzyme to target in pancreatic cancer 30873 1IDO2 an active enzyme to target in pancreatic cancer 30873 2
... ,Animal Study Confirms Caprospinol,s (SP-233) Abi...ells to Recover Memory Function , In Vivo ,Proof o...en Removing Beta Amyloid Plaque and Memory Recover...amaritan,Pharmaceuticals Inc. (AMEX:LIV), a develo... has confirmed Caprospinol,s (SP-233),efficacy in ...
...ENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix Me... clinical collaborators,reported new clinical data...erum levels of the Company,s patented AtherOx(TM),...as presented at,the XXIst Congress of the Internat...in Geneva, Switzerland., Data released this week s...
Other Medicine Technology:Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 2Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4
(Date:1/8/2009)...ole introduces Senator Daschle at his confirmation...man Services , , , WASHINGTON, Jan. 8 /PRNews... founding board member Senator Tom Daschle, nomine...etary, was introduced by fellow BPC founder and fr...today. The hearing was convened by the Senate Heal...
(Date:1/8/2009)...at St. Jude Children,s Research Hospital have demo...pneumonia following influenza. They found that the...ill bacteria by inhibiting their protein synthesis...eatment with the "beta-lactam" antibiotic ampicill... , The finding is important because pneumonia, r...
(Date:1/8/2009)...RANCISCO, Jan. 8 Medivat...David Hung, M.D., president and chief,executive o...n Healthcare,Conference on Wednesday, January 14,...ncis Hotel in San Francisco. , Dr. Hung wil...al,development programs for Dimebon for Alzheimer...
(Date:1/8/2009)...a., Jan. 8 Cephalon, In...aldino, Jr., Ph.D., Chairman and CEO will present...eld on January 13, 2009 in San Francisco, CA at ap... Time). The presentation will be webcast live on t...site. , , The webcast will be archived for one...
Breaking Medicine News(10 mins):Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3
...phy from Newfoundland has been charged of intentio...positive woman who has pleaded guilty against a se...ressed that she did not sexually assault any soldi...ve asked its official to undergo medical tests if ...
...onclave will be opened by India’s Health Minister ...ave will review the progress made towards achievin...h. The conclave is expected to make recommendation...a for achieving the goals, according to the Confed...
...g revelation, a recent survey by the Confidential ...dicates that there are at least 50 cases // a year...pts. The systematic investigation by CEMACH, whic...of Britain's six royal colleges of medicine, comes...
... a latest survey, there is a steady decline in the... Britain // . The findings were presented at the ...th of this month by researchers from Cancer Resear...n of Cancer Registries. The survey revealed, that...
Other Medicine News:
...hip Camera System offers 800+ lines of resolution ...ic gain control, and white balance features in a u...stem for Microscopic Application, Domestic (MS 100...CCU) with power cord and video cables , (MS 1000-0...
Provides a combination of concentrated cold / hot and compression for the elbow
Provides a combination of concentrated cold / hot and compression for the neck
Provides a combination of concentrated cold / hot and compression for the ankle
Medicine Products: